Research News
View articles by month and year
1–7 of 7 articles
-
Vitamin D Levels May Be Reason Some Women Benefit from Zometa Added to Chemo
New results from a large study suggest that postmenopausal women diagnosed with early-stage breast cancer who had adequate vitamin D levels got more benefits from Zometa combined with chemotherapy than women who had low vitamin D levels.
-
Xgeva Better Than Zometa at Reducing Risk of Bone Problems in Women with Metastatic Disease
Research suggests that Xgeva is better than Zometa at reducing the risk of bone complication and improves quality of life more in women diagnosed with metastatic breast cancer that has spread to the bones.
-
Zometa Can Help Reduce Recurrence Risk of Hormone-Receptor-Positive Disease
Results from three studies all suggest that Zometa can help reduce the risk of cancer recurrence when it's started right after surgery to treat hormone-receptor-positive early-stage breast cancer in postmenopausal and older premenopausal women.
-
Xgeva More Likely to Cause Osteonecrosis of the Jaw in Women Diagnosed with Advanced-Stage Breast Cancer
Research suggests that people diagnosed with advanced-stage breast or prostate cancer who get Xgeva are about twice as likely to develop osteonecrosis of the jaw compared to people with other advanced-stage cancers treated with Xgeva.
-
Long-Term Bisphosphonate Use Linked to Atypical Fracture Risk
Women who take bisphosphonates for more than 5 years have a higher risk of breaking a leg bone in an unusual spot.
-
Xgeva Better Than Zometa at Reducing Risk of Breast Cancer Bone Problems
Research has found that Xgeva (chemical name: denosumab), a new targeted therapy medicine, is better than Zometa at lengthening the time before bone complications develop in women diagnosed with breast cancer that has spread to the bones.
-
Xgeva Slightly Better Than Zometa at Reducing Breast Cancer Bone Complications
Research has found that Xgeva (chemical name: denosumab), a new targeted therapy medicine, is somewhat better than Zometa at lowering the risk of bone complications in women diagnosed with breast cancer that has spread to the bones.
1–7 of 7 articles
